• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Gardiner Sandra A.

    3/21/25 6:59:40 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care
    Get the next $ADGM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GARDINER SANDRA A.

    (Last) (First) (Middle)
    C/O ADAGIO MEDICAL HOLDINGS, INC.
    26051 MERIT CIRCLE, SUITE 102

    (Street)
    LAGUNA HILLS CA 92653

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Adagio Medical Holdings, Inc. [ ADGM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Non-qualified stock option (right to buy)(1) $0.865 03/20/2025 A 90,000 (1) 07/31/2034 Common Stock 90,000 $0 90,000 D
    Explanation of Responses:
    1. Stock option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Option will vest over a three-year period, whereby 1/36th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of July 31, 2024.
    /s/ John Dahldorf, Attorney-in-Fact 03/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ADGM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adagio Medical to Present at the BofA Securities 2025 Health Care Conference

      Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities Health Care Conference on Tuesday, May 13, 2025, at 9:20 a.m. PT at the Encore Hotel in Las Vegas, NV. Presentation Information A live and recorded webcast of the presentation will be available at: https://bofa.veracast.com/webcasts/bofa/healthcare2025/id5FQ7Pq.cfm About Adagio Medical Adagio Medical is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietar

      5/7/25 8:30:00 AM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • Adagio Medical Holdings, Inc. Receives FDA Breakthrough Device Designation for the vCLASTM Cryoablation System

      Agency's Breakthrough Device Designation Program Allows for Priority Review of Ablation Technology for Ventricular Tachycardia Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has received Breakthrough Device designation from the U.S. Food and Drug Administration ("FDA") for its vCLASTM Cryoablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia ("VT") in patients with ischemic or non-ischemic structural heart disease. Adagio's vCLASTM Cryoablation System, which is currently the subject of an I

      4/17/25 8:30:00 AM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • Adagio Medical Appoints Deborah Kaster as Chief Business Officer

      Adagio Medical (NASDAQ:ADGM), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, is pleased to announce the appointment of Deborah Kaster as Chief Business Officer (CBO). Kaster brings more than 25 years of leadership experience in strategy, mergers and acquisitions, corporate finance, investor relations and strategic communications in the medical technology sector. Most recently, Kaster served as Vice President of Investor Relations at Shockwave Medical, where she played a pivotal role in the company's growth from IPO to its acquisition by Johnson & Johnson. During her time at Shockwave, the company's stock price appreciated nearly 2000%, a testame

      3/31/25 4:01:00 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care

    $ADGM
    SEC Filings

    See more
    • SEC Form 424B3 filed by Adagio Medical Holdings Inc

      424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

      5/1/25 6:05:38 AM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Adagio Medical Holdings Inc

      424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

      5/1/25 6:03:54 AM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Adagio Medical Holdings Inc

      10-K/A - Adagio Medical Holdings, Inc. (0002006986) (Filer)

      4/30/25 4:05:27 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care

    $ADGM
    Leadership Updates

    Live Leadership Updates

    See more
    • Adagio Medical Appoints Deborah Kaster as Chief Business Officer

      Adagio Medical (NASDAQ:ADGM), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, is pleased to announce the appointment of Deborah Kaster as Chief Business Officer (CBO). Kaster brings more than 25 years of leadership experience in strategy, mergers and acquisitions, corporate finance, investor relations and strategic communications in the medical technology sector. Most recently, Kaster served as Vice President of Investor Relations at Shockwave Medical, where she played a pivotal role in the company's growth from IPO to its acquisition by Johnson & Johnson. During her time at Shockwave, the company's stock price appreciated nearly 2000%, a testame

      3/31/25 4:01:00 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • Adagio Medical Announces Appointment of Accomplished Medical Device Leader Todd Usen as Chief Executive Officer and Director

      Founding Chief Executive Officer and Director Olav Bergheim to Depart Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company" or "Adagio")), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that founder Olav Bergheim departed as Chief Executive Officer ("CEO") and Chairperson of the Board of Directors of the Company, effective December 13, 2024. Concurrently, the Company announced the appointment of Todd Usen, as Chief Executive Officer and Director of the Company and Orly Mishan, as Chairperson of the Board of Directors, effective December 13, 2024. Mr. Bergheim will serve as an advisor to the Company and will support Mr. Usen

      12/16/24 8:00:00 AM ET
      $ADGM
      Medical/Dental Instruments
      Health Care

    $ADGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider George Dan

      3 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

      4/28/25 5:23:28 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Cox James L

      4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

      3/21/25 7:00:18 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Gardiner Sandra A.

      4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

      3/21/25 6:59:40 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care

    $ADGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Adagio Medical Holdings Inc

      SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

      11/13/24 4:30:17 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Adagio Medical Holdings Inc

      SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

      8/12/24 4:22:57 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care